BioCryst Pharmaceuticals (BCRX) to Release Quarterly Earnings on Thursday

BioCryst Pharmaceuticals (NASDAQ:BCRX) is expected to release its Q4 2025 results before the market opens on Thursday, February 26th. Analysts expect BioCryst Pharmaceuticals to post earnings of $0.06 per share and revenue of $151.32 million for the quarter. Interested persons can check the company’s upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Thursday, February 26, 2026 at 8:30 AM ET.

BioCryst Pharmaceuticals Stock Up 1.7%

BioCryst Pharmaceuticals stock opened at $7.58 on Tuesday. The stock has a 50-day moving average price of $7.09 and a 200 day moving average price of $7.40. The company has a market capitalization of $1.60 billion, a price-to-earnings ratio of -151.60 and a beta of 0.83. BioCryst Pharmaceuticals has a 52 week low of $6.00 and a 52 week high of $11.31.

Wall Street Analysts Forecast Growth

Several research firms have recently commented on BCRX. Royal Bank Of Canada dropped their price objective on shares of BioCryst Pharmaceuticals from $14.00 to $13.00 and set an “outperform” rating on the stock in a report on Friday, January 30th. Evercore began coverage on shares of BioCryst Pharmaceuticals in a research report on Wednesday, February 18th. They set an “outperform” rating and a $17.00 target price for the company. Citizens Jmp lowered their price target on shares of BioCryst Pharmaceuticals from $27.00 to $25.00 and set a “market outperform” rating on the stock in a report on Wednesday, November 5th. Needham & Company LLC reduced their price objective on BioCryst Pharmaceuticals from $20.00 to $18.00 and set a “buy” rating for the company in a research note on Tuesday, November 4th. Finally, Barclays decreased their price objective on BioCryst Pharmaceuticals from $11.00 to $9.00 and set an “equal weight” rating for the company in a report on Tuesday, November 4th. Ten investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $19.64.

Insiders Place Their Bets

In other news, insider Alane P. Barnes sold 91,004 shares of the business’s stock in a transaction that occurred on Monday, December 1st. The stock was sold at an average price of $7.10, for a total transaction of $646,128.40. Following the transaction, the insider directly owned 416,152 shares in the company, valued at $2,954,679.20. The trade was a 17.94% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Over the last 90 days, insiders have sold 183,453 shares of company stock valued at $1,330,965. Company insiders own 5.10% of the company’s stock.

Hedge Funds Weigh In On BioCryst Pharmaceuticals

A number of institutional investors have recently added to or reduced their stakes in BCRX. Royal Bank of Canada grew its holdings in BioCryst Pharmaceuticals by 2.4% in the 1st quarter. Royal Bank of Canada now owns 63,463 shares of the biotechnology company’s stock valued at $476,000 after buying an additional 1,458 shares in the last quarter. Cetera Investment Advisers boosted its position in shares of BioCryst Pharmaceuticals by 13.8% during the 4th quarter. Cetera Investment Advisers now owns 12,330 shares of the biotechnology company’s stock valued at $96,000 after acquiring an additional 1,494 shares during the last quarter. Captrust Financial Advisors grew its holdings in shares of BioCryst Pharmaceuticals by 7.4% in the second quarter. Captrust Financial Advisors now owns 22,105 shares of the biotechnology company’s stock valued at $198,000 after purchasing an additional 1,527 shares during the period. Creative Planning grew its holdings in shares of BioCryst Pharmaceuticals by 2.6% in the third quarter. Creative Planning now owns 88,477 shares of the biotechnology company’s stock valued at $672,000 after purchasing an additional 2,280 shares during the period. Finally, Inceptionr LLC increased its position in BioCryst Pharmaceuticals by 20.5% during the fourth quarter. Inceptionr LLC now owns 13,631 shares of the biotechnology company’s stock worth $106,000 after purchasing an additional 2,317 shares during the last quarter. Hedge funds and other institutional investors own 85.88% of the company’s stock.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc is a clinical‐stage biotechnology company headquartered in Durham, North Carolina, that focuses on the discovery and development of novel, oral small‐molecule medicines for rare and serious diseases. Since its founding in 1986, the company has leveraged structure‐based drug design to advance a pipeline of targeted therapeutics designed to address underlying disease mechanisms rather than just treat symptoms.

The company’s first commercial product, Orladeyo (berotralstat), is an oral kallikrein inhibitor approved for the prophylactic treatment of hereditary angioedema (HAE) in both the United States and Europe.